ARTICLE | Emerging Company Profile
Bispecific simplicity
How EpimAb improves potency, stability and immunogenicity of bispecifics
February 4, 2017 1:02 AM UTC
EpimAb Biotherapeutics Inc. is developing bispecific antibodies designed to be more potent and stable, less immunogenic and easier to manufacture than those made by competing platforms.
The company’s Fabs-In-Tandem Immunoglobulin (FIT-Ig) technology retains all four Fab domains of the parent mAbs and uses a full-length wild-type human Fc domain with no mutations or linker chemistry...
BCIQ Company Profiles